In a randomized, double-blind, placebo-controlled trial, fezakinumab (an anti-IL-22 monoclonal antibody) had good efficacy and safety in treating adult patients with moderate-to-severe AD, confirming IL-22 as a crucial driver of AD (83). The gene discussed is IL22; the disease is Alzheimer disease.